osteoporosis-arthroplasty-2017-scientifictracks

10 / 29

Page 28
Notes:
Volume 3, Issue 4 (Suppl) J Clin Exp Orthop
ISSN:2471-8416 Osteoporosis and Arthroplasty 2017
December 04-05, 2017
&
11th International Conference on
Joint Event
OSTEOPOROSIS, ARTHRITIS & MUSCULOSKELETAL DISORDERS
December 04-05, 2017 | Madrid, Spain
10th INTERNATIONAL CONFERENCE ON ARTHROPLASTY
Clinical experience in 10 patients implanted with a contralateral prophylactic medical device in case of
first low-energy hip fracture due to osteoporosis
Szpalski Marek1, Le Huec Jean Charles2, Jayankura Mark3 and Reynders Pieter4
1Hôpitaux Iris Sud, Belgium
2Pellegrin Hospital, France
3Erasme Hospital, Belgium
4University Hospital of Brugmann, Belgium
An innovative implant, Y-STRUT® (Hyprevention, France), was developed to provide prophylactic reinforcement of the proximal
femur in patients suffering from a first hip fracture due to osteoporosis. We present our clinical experience on the first 10 patients
implanted between February 2013 and December 2016. Prophylactic consolidations were performed under the same anesthesia of a
hip fracture surgical treatment in the opposite side for patients at high risk of contralateral fracture. A multicenter prospective pilot
study is ongoing on a planned cohort of 15 osteoporotic patients. Mid-term tolerance and safety of the studied device are assessed
with several criteria, such as walking recovery, pain, radiographic control and adverse events. Clinical efficacy is evaluated through
the occurrence of fractures. Ten elderly patients (mean 82±7 yrs.) were implanted because of a severe osteoporosis (mean T-score
-3.64±0.8) resulting in first hip fractures. Follow-up ranges from 4 to 46 months and in all patients, wound healing was achieved,
with no case of wound infection, bleeding, or inflammation. Radiographic exams performed at 3-month-follow-up revealed that the
device was well integrated in the bone. No hospitalization lengthening was needed and all patients recovered walking and no pain was
reported at 3 weeks (mean VAS was 0.9±0.7). Several post-operative falls were reported and no post-operative fracture was observed.
Preliminary results from this study demonstrated the tolerance and safety as well as the short-term clinical efficacy of the studied
device. Additional data need to be recorded on a greater number of subjects and longer follow-up to confirm the clinical benefits of
Y-STRUT® implantation.
Biography
Szpalski Marek is the President of the Orthopedic Surgery and Traumatology Department at Iris South Teaching Hospital/ Moliere Longchamp in Brussels
(Belgium). He is a Professor of Orthopedic at Libre University of Brussels and Professor of Orthopedic at New York University. He is Co-Inventor of the study
device, Y-STRUT®.
Szpalski Marek et al., J Clin Exp Orthop 2017, 3:4(Suppl)
DOI: 10.4172/2471-8416-C1-002